CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give CRISPR Therapeutics a “Moderate Buy” consensus: Of 18 analysts, 10 recommend buying, one strongly recommends buying, six rate it a hold, and one recommends selling. The average 12-month price target is $68.06 versus a recent share price of $51.72.
• CRISPR Therapeutics reported a quarterly loss of $0.94 per share on $10.18 million in revenue, and analysts expect a full-year loss of $4.47 per share. The company continues to develop CRISPR/Cas9 gene-editing medicines, led by approved therapy Casgevy.
• Institutional investors own 69.2% of the company, while several funds recently increased or initiated positions. CRSP has traded between $44.12 and $78.48 over the past year and has a market capitalization of approximately $5 billion.

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has received an average rating of "Moderate Buy" from the eighteen analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $68.0556.

Several equities research analysts recently commented on CRSP shares. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Citizens Jmp reissued a "market outperform" rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Wall Street Zen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the company an "equal weight" rating in a research note on Thursday, June 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Friday, July 17th.

CRISPR Therapeutics Price Performance

CRSP stock opened at $51.72 on Monday. CRISPR Therapeutics has a 52 week low of $44.12 and a 52 week high of $78.48. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of -10.87 and a beta of 1.76. The firm's 50-day moving average is $53.49 and its two-hundred day moving average is $52.94. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The company had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. On average, analysts forecast that CRISPR Therapeutics will post -4.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in CRSP. Versant Capital Management Inc grew its position in CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company's stock worth $25,000 after buying an additional 296 shares during the last quarter. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $26,000. Rothschild Investment LLC boosted its stake in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company's stock worth $29,000 after acquiring an additional 502 shares in the last quarter. Finally, Strategic Wealth Investment Group LLC acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter worth $36,000. Institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG NASDAQ: CRSP is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company's programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient's blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.